Game-changing obesity drugs go mainstream: what scientists are learning

* NEWS * 23 May 2023 Studies tackle who’s most likely to lose weight on the new generation of anti-obesity medications. By * Mariana Lenharo * Mariana Lenharo A new generation of drugs is

revolutionizing the treatment of obesity and astonishing researchers with their potency. The drug semaglutide, for example, enabled one-third of clinical-trial participants to shed at least

20% of their body weight1. Tirzepatide, a competing therapy, achieved similar results in more than half of study participants2. ACCESS OPTIONS Access Nature and 54 other Nature Portfolio

journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 51 print issues and online access $199.00 per year only

$3.90 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS:

_Nature_ 618, 17-18 (2023) _doi: https://doi.org/10.1038/d41586-023-01712-8_ REFERENCES * Wilding, J. P. H. _et al._ _N. Engl. J. Med._ 384, 989–1002 (2021). Article  PubMed  Google Scholar

  * Jastreboff, A. M. _et al._ _N. Engl. J. Med._ 387, 205–216 (2022). Article  PubMed  Google Scholar  * Acosta, A. _et al._ _Obesity_ 29, 662–671 (2021). Article  PubMed  Google Scholar  *

Jensterle, M. _et al._ _Endocr. Abstr._ 81, OC5.2 (2022). Article  Google Scholar  * Rubino, D. _et al._ _JAMA_ 325, 1414–1425 (2021). Article  PubMed  Google Scholar  Download references

RELATED ARTICLES SUBJECTS LATEST ON: Medical research Metabolism